Archives of Depression and Anxiety
|
|
- Tracey Cain
- 6 years ago
- Views:
Transcription
1 Medical Group Archives of Depression and Anxiety ISSN: DOI CC By Martin H Teicher 1,2 *, Danielle M Webster 3 and Steven B Lowen 4 1 Department of Psychiatry, Harvard Medical School, USA 2 Developmental Biopsychiatry Research Program and Clinical Chronobiology Laboratory, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA 3 Tufts University, Health Service Department, 124 Professors Row, Medford, MA Omni Claim, Inc, 300 Unicorn Park Drive, Woburn, MA 01801, USA Dates: Received: 17 May, 2017; Accepted: 25 May, 2017; Published: 26 May, 2017 *Corresponding author: Martin H Teicher, Mclean Hospital, Developmental Biopsychiatry Research Program, 115 Mill Street, Belmont, MA , USA, Tel: (617) ; Fax: (617) ; Keywords: SAD; Winter depression; Bupropion; Gender differences Research Article Bupropion Sustained released versus Placebo for seasonal affective Disorder Abstract Background: The majority of seasonal affective disorder (SAD) studies have evaluated the use of light or selective serotonin reuptake inhibitors (SSRI). The purpose of the present study was to evaluate bupropion sustained-released (SR), a non-ssri antidepressant, for the treatment of SAD. Method: Forty-one adults meeting DSM IV criteria for SAD were recruited into a six-week, randomized, double-blind, placebo-controlled trial. Participants started on bupropion SR 150 mg QD (or equivalent placebo pills) and titrated up to 200 mg BID if tolerated by week 4. Participants were evaluated weekly with SIGH-SAD and self-reported Kellner Symptom Questionnaire (SQ). Mixed effects growth models and receiver operating characteristic (ROC) analyses were used to compare treatments. Results: Analysis was done on the 36 participants who completed at least 2 weeks of treatment, as per protocol. Thirty-four participants completed the entire protocol; two participants receiving placebo dropped out during weeks 3 and 5. Sixteen participants (7 male, 9 female, years, mean+sd) received bupropion SR and 20 participants (8 males, 12 females, years) received placebo. Participants receiving bupropion SR had a more rapid reduction in atypical SIGH-SAD depressive symptoms and lower depression scores across time on the SQ. ROC analyses revealed that positive effects of bupropion SR on total SIGH-SAD scores were more evident in males than females. Bupropion SR was well tolerated. Conclusion: Bupropion SR may be beneficial for the treatment of SAD, but larger randomized placebocontrolled studies are warranted. Introduction Recurrent major depression with seasonal pattern (SAD) may affect between 1% and 3% of adults living far from the equator [1]. Treatment studies have focused on the use of light. However, many patients find light therapy inconvenient, or require medications as sole or adjunctive treatment. Relatively few controlled medication trials have been reported. Briefly, several agents have been found to be ineffective. These include atenolol [2], as a suppressor of melatonin production, melatonin itself [3], levodopa plus carbidopa [4] and cyanocobalamin [5], as an agent that facilitates entrainment of circadian rhythms. Preliminary positive results have been obtained with d-fenfluramine [6], low-dose morning propranolol [7] and tryptophan [8,9]. Randomized double-blind placebo controlled trials of conventional antidepressants have demonstrated modest effects. Moclobemide (a reversible MAO-A inhibitor) decreased atypical depression scores compared with placebo but had no significant effect on the Montgomery and Asberg Depression Rating Scale or Clinical Global Improvement scores [10]. Using the 29-item modified Structured Hamilton depression Rating Scale (SIGH-SAD) [11], Lam et al. [12], found that fluoxetine was significantly more effective than placebo based on the percent of participants with a 50% or greater reduction in depression scores (59% vs. 34%), but not in terms of average depression scores. A large-scale Canadian study found that fluoxetine (20 mg/d) was as effective as 10,000 lux light therapy, but interpretation is clouded by lack of a placebo arm [13]. Moscovitch et al. [14], reported superiority of sertraline over placebo producing a 52% vs. 43% reduction in Hamilton Depression Ratings. An open trial of bupropion for SAD reported marked efficacy [15]. Since many patients with SAD have symptoms associated with atypical depressions including psychomotor retardation, carbohydrate craving, and hypersomnia, and may have a mild form of bipolar disorder [16], bupropion appears to be a good theoretical choice [17,18]. Bupropion was evaluated in a large multicenter international study for its potential to prevent recurrence of SAD when initiated prior to the fall-winter season. Bupropion produced a 44% relative risk reduction versus placebo [19] and the FDA subsequently approved bupropion for 009
2 this purpose. Part of the scientific rationale for conducting a trial of bupropion for prophylaxis of SAD was an unpublished randomized double-blind placebo controlled treatment trial. This is a report of the results of that study conducted during the fall/winter 1997/98 and 1998/99. Method All participants gave written informed consent for this IRB-approved study after procedures and possible side effects were fully explained. Participants were recruited from the community by newspaper advertisements. The study was designed as a double-blind, randomized, parallel group placebo control trial. Entry requirements included a diagnosis of Major Depression, Recurrent with Seasonal Pattern based on DSM-IV and Rosenthal NIMH criteria [16]. Briefly, these criteria require that individuals have a history of recurrent depressive episodes that regularly recur and remit during specific times of the year, this pattern must have lasted at least two years with no nonseasonal episodes and that the number of seasonal episodes substantially outnumber any non-seasonal episodes. Participants also had to have a baseline 29-item Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement (SIGH SAD) score of at least 20, to be medically healthy and on no medications except hormone replacement therapy (HRT) or oral contraceptives. Participants also had to indicate that they had no plans to travel to tropical locations during the time that there were enrolled in the study. Individuals with anorexia, bulimia or history of seizures were excluded. Potential participants who met these criteria then received a blood test to assess thyroid status and returned 1-2 weeks later for reassessment. On the second baseline assessment they also needed to have a SIGH- SAD score of at least 20 and normal thyroid profile. Those who did were randomized to drug or placebo. Efficacy measurements included interviewer-based SIGH SAD scores [11] and self-reported symptoms of depression on Kellner s Symptom Questionnaire (SQ) [20]. Potential adverse events were assessed each week by inquiring about specific side effects including dry mouth, nausea, weight loss, insomnia, anxiety, agitation, seizures, dizziness and constipation. Following the second baseline measure participants received 6 weeks of treatment on drug or placebo. Bupropion SR was introduced at 150 mg once daily, and titrated to 200 mg twice daily by week 4, if tolerated. Participants receiving placebo followed the same titration schedule. Placebo-controlled trials of light therapy indicate that conventional analysis of mean improvement on SIGH-SAD scores often fails to detect a significant light-placebo difference [21,22]. Light therapy emerges as superior to placebo, based on percentage of participants showing full clinical remission, and by Receiver-Operating Characteristic (ROC) analysis of the data [22]. Unlike conventional statistical tests, ROC analyses make no assumptions about the distribution of the data or the scaling properties of the measure. It also does not force the investigator to make an arbitrary decision that a specific score or percent change criteria is required for improvement or remission. Rather, it portrays the differential pattern of response of patients on drug versus placebo across the entire range of scores. Assuming that there was no difference between drug and placebo then the area under the ROC curve (AUC ROC) would be 0.5, and the ROC curve would follow a straight line from the origin (0,0) to the joint maximum (1,1). Comparing the actual pattern of drug-placebo response to the theoretical null effect line provides a powerful means of detecting a differential pattern of response to drug, and also provides novel insight into the type of therapeutic response obtained. ROC response was analyzed in two ways. First we assessed the significance of the area under the curve, which is equivalent to the Mann Whitney U test or Wilcoxon rank sum test. Second, we used the Kolmogorov-Smirnov test [23], to examine maximal degree of departure from the null effect chance line to determine if there was a differential pattern of response to drug versus placebo. The Fisher Exact Test was used to compare percentage of participants meeting remission criteria at endpoint on drug versus placebo. Finally, hierarchical growth models [24], were used to compare drug versus placebo differences in time course of response based on ratings at baseline and during each of the 6 treatment weeks. Because the sample size was modest and this was a preliminary study we used a directional one-tailed criteria P 1T < 0.05 testing whether participants on bupropion showed a superior response than participants on placebo, or two-tailed directionless criteria of P < 0.1. Results Forty-six participants were recruited and came in for their first baseline assessment. Five were excluded from the study (2 due to elevated TSH levels, 3 for work schedule or vacation conflicts) prior to medication assignment. Of the 41 patients to begin the protocol, 5 dropped out (3 on medication, 2 on placebo) before completing two weeks of treatment (2 sought other treatment, 3 experienced side effects). Thirty-six participants who completed at least two weeks of treatment were included in the analyses, as per protocol. Thirty-four of the 36 participants completed all six weeks of treatment. Two participants on placebo withdrew from the study. One participant with minimal placebo response withdrew at week three because of side effects. The other with a moderate placebo response was withdrawn at week five due to an unrelated medical problem. The last observations from these participants were carried forward to endpoint. Sixteen participants (7 males, 9 females, 46.5 ± 9.6 years, mean ± SD) received bupropion SR for 6 weeks and 20 participants (8 males, 12 females, 48.2 ± 8.8 years) received placebo for an average of 5.8 weeks. Initial group description is shown in table 1. At endpoint, full clinical remission (50% or greater decrease in SIGH-SAD scores and final score of < 8) occurred in n=4 (20%) participants on placebo and in n=7 (44%) participants on bupropion SR. Hence, the Odds Ratio for remission on drug versus placebo was 3.00 {95% CI }, but was not significant given the limited sample size (Fisher exact 010
3 P 1T = 0.12). Hierarchical growth curve analysis indicated that the SIGH-SAD total scores were better fit by a 2-component piecewise growth model with first-order autoregressive (AR1) correlation than by a 1 component AR1 model (LR = 49.3, P < ), linear model (LR = 64.92, P <0.0001), or quadratic model (LR = 25.7, P < ). As seen in figure 1 there was a marked drop in SIGH-SAD scores from baseline to first posttreatment visit (T1: F 1,212 = 48.50, P < ) and a gradual reduction from first to sixth post-treatment visit (T2: F 1,212 = 30.33, P < ). However, there was no significant overall difference between participants receiving bupropion versus placebo (F 1,33 = 0.29, P > 0.5) nor any significant treatment by T1 (F 1,212 = 1.85, P = 0.17) or treatment x T2 interactions (F 1,212 = 1.72 P = 0.19). Total SIGH-SAD score represent the sum of the standard 21-item Hamilton Depression Rating Scale (HDRS-21) plus an 8-item atypical addendum that includes features such as hypersomnia, carbohydrate craving and reverse diurnal variation. These atypical features are included in the SIGH- SAD as they tend to better characterize individuals with seasonal depression than more typical depressive symptoms. There was no evidence for medication versus placebo differences on HDRS-21 scores; however there were significant T1 x treatment (F 1,212 = 3.75, P = 0.05) and T2 x treatment (F 1, 212 = 3.19, P < 0.08) interactions on atypical depression scores (Figure 2). As seen in figure 3, AUC ROC for final SIGH-SAD scores (AUC = 0.548, p = 0.32) was not significant, but there was evidence for a differential pattern of response. The ROC curve deviated significantly from the null effect line with the greatest deviation occurring around final SIGH-SAD scores of 7 (P < 0.05). ROC analysis demonstrated distinctly different drug response patterns in males vs. females. As illustrated in figure 3, the ROC curve for males departed significantly from the null effect line, particularly at scores of 7-9. All male participant scores between 4-7 (remission) occurred on drug while all scores between (no benefit) occurred on placebo. In contrast, females showed a divergent response pattern. Virtually all scores between (partial response) occurred in women on placebo. Nearly all scores between 3-7 (remission) and nearly all scores between (no benefit) occurred on bupropion SR. Hence, women receiving bupropion SR either did quite well or reported more symptoms than women receiving placebo. Table 1: Initial ratings for medication and placebo groups. Measures Bupropion Placebo t-test df p AGE ± ± p>0.6 SQ Anxiety 8.38 ± ± p>0.1 SQ Depression 9.94 ± ± p>0.1 SQ Somatization 8.81 ± ± p>0.7 SQ Anger-Hostiity 9.38 ± ± p>0.9 SIGH-SAD Typical ± ± p>0.5 SIGH-SAD Atypical ± ± p>0.2 SIGH-SAD Total ± ± p>0.6 SIGH-SAD Structured Interview Guide to the Hamilton Depression Rating Scale, Seasonal Affective Disorder version. SQ Kellner Symptom Questionnaire. Total SIGH-SAD (LS means) Weekly Ratings med_placebo med placebo Figure 1: Piecewise hierarchical growth model showing least square mean total depression scores (SIGH-SAD) across time in participants receiving bupropion- SR versus placebo. Week 0 is their unmedicated baseline score followed by six successive weeks on bupropion or placebo. Atypical Depression Scores (LS means) Weekly Ratings med_placebo med placebo Figure 2: Piecewise hierarchical growth model showing least square mean atypical depression scores (8 items) across time in participants receiving bupropion-sr versus placebo. There was evidence for a therapeutic effect on the hierarchical piecewise growth curve analysis of self-reported SQ depression scores (F 1,34 = 2.95, P = 0.095) indicating that participants receiving bupropion had lower mean scores across time, but there were no significant time x treatment interactions. ROC analysis of SQ depression scores showed trend-level drug placebo difference in final scores (AUC ROC = 0.639, P 1T < 0.08). The Kolmogorov-Smirnov test showed clear evidence for a significant departure from the null effect line at final SQ scores of 5 (P < 0.02), indicating a differential pattern of response with more participants on bupropion showing very low depression scores than on placebo. In comparison with other studies that asked Have you felt different in any way since your last visit?, we specifically inquired about common side effects each week. Overall bupropion SR was well tolerated. The only significant side effect was constipation reported by 6 (37%) participants on bupropion SR and 2 (10%) on placebo (Fisher Exact, P 1T = 0.058). Interestingly 5 out of 9 females on bupropion SR reported this as a side effect, but constipation was not related to degree of antidepressant response. 011
4 Discussion The results of this small randomized, double-blind, placebo-controlled study were consistent with a previous open trial study of bupropion in SAD [15]. Participants receiving bupropion SR in the current study showed more rapid reduction in atypical depression scores and lower mean levels of selfreported SQ depression across ratings. All of the other findings, such as the 3-fold greater odds on bupropion versus placebo of showing a complete recovery, were in the right direction, but non-significant given the limited sample size. The finding that there were significant time by treatment interactive effects on atypical but not typical depression scores was consistent with result reported by Lingjaerde et al. [10], using moclobemide. It was also interesting that males and females displayed different response patterns on ROC analysis of final SIGH- SAD depression ratings. Bupropion SR was associated with low scores and placebo with high scores in males. Women receiving bupropion SR clustered into two groups. Some had a good therapeutic response while others were more symptomatic than women receiving placebo. Conventional analyses comparing average group scores or percent remission rates would fail to delineate these differential response patterns. It should be noted that the ROC curve for female SIGH-SAD scores was unusual, and proper ROC curves for signal detection never have a concave upward appearance. However, this is not necessarily true using ROC to analyze drug effects, as medications can produce both improvement and worsening in a group of participants. A Monte-Carlo simulation of mixed response to drug confirmed that ROC curves of this shape arise, as predicted. Hence, these unusual ROC curves are consistent with mixed response to medication. One possibility is that bupropion SR may exert a more robust catecholaminergic response in males than females due to the complex effects of estrogen on catecholamine neurotransmission [25]. Although there were 5 women on bupropion SR who had reached menopause, all but one received hormone replacement therapy. Three women age 50 and over had an excellent response to bupropion while four had a minimal response. Younger women had an intermediate response. These results are compatible with a re-analysis of antidepressant studies that found that depressed men have a better therapeutic response to imipramine than depressed premenopausal women [26]. Figure 3: Receiver operating characteristic (ROC) analysis of total SIGH-SAD scores at endpoint in entire sample and in male and female subsamples. The dotted line in each graph is the null effect line. There was no significant overall benefit of bupropion on SIGH-SAD scores for the entire sample based on area under the ROC curve. However, there was a differential pattern of response to bupropion versus placebo based on Kolmogov-Smirnof analyses, as the distribution of probability scores deviated significantly from the chance -null effect line around SIGH-SAD scores of 7. Males and females showed different patterns of responses. Men showed a potential drug advantage, with a ROC area of Men deviated significantly from the null effect line, particularly at scores of 7-9 and In contrast, women showed no overall benefit on bupropion, as some did quite well but others had scores higher than women taking placebo. Number in circles are total SIGH-SAD depression scores at each point. Study limitations include a 6-week treatment duration with only 3 weeks on bupropion SR at 200 mg BID. The milder winter seasons (fall/winter 97/98 and 98/99) may have affected our participant population and severity of reported symptoms. Most important, the sample size was small, especially for male and female subgroup analysis. Nevertheless, this pilot study warrants further evaluation in larger controlled trials. Acknowledgments Supported, in part, by Glaxo Wellcome, Inc, now GlaxoSmithKline, as an investigator initiated study. The company played no role in the design, analysis or reporting of 012
5 results. We thank Carol A. Glod PhD for assistance in subject recruitment and assessment. References 1. Levitt AJ, Boyle MH, Joffe RT, Baumal Z (2000) Estimated prevalence of the seasonal subtype of major depression in a Canadian community sample. Can J Psychiatry 45: Link: 2. Rosenthal NE, Jacobsen FM, Sack DA, Arendt J, James SP, et al.,. (1988) Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am J Psychiatry 145: Link: 3. Wirz JA, Graw P, Krauchi K, Gisin B, Arendt J, et al.,. (1990) Morning or nighttime melatonin is ineffective in seasonal affective disorder. J Psychiatr Res 24: Link: 4. Oren DA, Moul DE, Schwartz PJ, Wehr TA, Rosenthal NE (1994) A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis. J Clin Psychopharmacol 14: Link: 5. Oren DA, Teicher MH, Schwartz PJ, Glod C, Turner EH, et al.,. (1994) A controlled trial of cyanocobalamin (vitamin B12) in the treatment of winter seasonal affective disorder. J Affect Disord 32: Link: 6. O Rourke D, Wurtman JJ, Wurtman RJ, Chebli R, Gleason R (1989) Treatment of seasonal depression with d-fenfluramine. J Clin Psychiatry 50: Link: 7. Schlager DS (1994) Early-morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry 151: Link: 8. Ghadirian AM, Murphy BE, Gendron MJ (1998) Efficacy of light versus tryptophan therapy in seasonal affective disorder. J Affect Disord 50: Link: 9. McGrath RE, Buckwald B, Resnick EV (1990) The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry 51: Link: Lingjaerde O, Reichborn-Kjennerud T, Haggag A, Gartner I, Narud K, et al.,. (1993) Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Acta Psychiatr Scand 88: Link: Williams JBW, Link MJ, Rosenthal NE, Terman M (1988) Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGHSAD). New York: New York Psychiatric Institute. Link: Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, et al.,. (1995) Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 152: Link: Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, et al.,. (2006) The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 163: Link: Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, et al.,. (2004) A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology 171: Link: Dilsaver SC, Qamar AB, Del Medico VJ (1992) The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 53: Link: Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, et al.,. (1984) Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41: Link: Goodnick PJ, Dominguez RA, DeVane CL, Bowden CL (1998) Bupropion slowrelease response in depression: diagnosis and biochemistry. Biol Psychiatry 44: Link: Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL (1998) The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 59: Link: Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, et al.,. (2005) Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 58: Link: Kellner R (1987) A symptom questionnaire. Journal of Clinical Psychiatry 48: Link: Terman M, Terman JS, Ross DC (1998) A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 55: Link: Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM (1998) Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 55: Link: Siegel S (1956) Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill. Link: Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team (2015) nlme: Linear and Nonlinear Mixed Effects Models. R package version 3: Gordon J, Perry K (1983) Pre- and postsynaptic neurochemical alterations following estrogen-induced striatal dopamine hypo- and hypersensitivity. Brain Research Bulletin 10: Link: Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157: Link: Copyright: 2017 Teicher MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 013
University of Groningen
University of Groningen Can winter depression be prevented by light treatment? Meesters, Ybe; Lambers, Petrus A.; Jansen, Jacob; Bouhuys, Antoinette; Beersma, Domien G.M.; Hoofdakker, Rutger H. van den
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More informationSeasonal Affective Disorder
Shining Some Light On Seasonal Affective Disorder Group 5: Manika Bhandari, Malika Bhola, Rucha Desai, Dhruvika Joshi, Abir Shamim Overview 1. 2. 3. 4. 5. 6. 7. Introduction Signs & Symptoms Epidemiology
More informationSeasonal Affective Disorder 1.0 Contact Hour Presented by: CEU Professor
Seasonal Affective Disorder 1.0 Contact Hour Presented by: CEU Professor 7 www.ceuprofessoronline.com Copyright 8 2007 The Magellan Group, LLC All Rights Reserved. Reproduction and distribution of these
More informationSeasonal Affective Disorder
Department of Psychiatry University of British Columbia Seasonal Affective Disorder Dr. Erin Michalak Sauder School of Business 5 th Annual Health and Safety Day October 21 st 2009 UBC Talk outline What
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationPersonality and seasonal affective disorder: Results from the CAN-SAD study
Journal of Affective Disorders 93 (2006) 35 42 www.elsevier.com/locate/jad Research report Personality and seasonal affective disorder: Results from the CAN-SAD study Murray W. Enns a,, Brian J. Cox a,
More informationdtb Clinical Review Management of seasonal affective disorder For the full versions of these articles see bmj.com
For the full versions of these articles see bmj.com Clinical Review From Drug and Therapeutics Bulletin Management of seasonal affective disorder dtb Drug and Therapeutics Bulletin Editorial Office, London
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationORIGINAL ARTICLE. A Controlled Trial of Timed Bright Light and Negative Air Ionization for Treatment of Winter Depression
ORIGINAL ARTICLE A Controlled Trial of Timed Bright Light and Negative Air Ionization for Treatment of Winter Depression Michael Terman, PhD; Jiuan Su Terman, PhD; Donald C. Ross, PhD Background: Artificial
More informationSeasonalAf f. Disorder
SeasonalAf f [REVIEW] by KATHRYN A. ROECKLEIN and KELLY J. ROHAN, PhD Ms. Roecklein and Dr. Rohan are from the Department of Medical and Clinical Psychology, Uniformed Services University of the Health
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationAtenolol in Seasonal Affective Disorder: A Test of the Melatonin Hypothesis
Atenolol in Seasonal Affective Disorder: A Test of the Melatonin Hypothesis Norman E. Rosenthal, M.D., Frederick M. Jacobsen, M.D., David A. Sack, M.D., Josephine Arendt, Ph.D., Stephen P. James, M.D.,
More informationORIGINAL ARTICLE. Circadian Time of Morning Light Administration and Therapeutic Response in Winter Depression
ORIGINAL ARTICLE Circadian Time of Morning Light Administration and Therapeutic Response in Winter Depression Jiuan Su Terman, PhD; Michael Terman, PhD; Ee-Sing Lo, PhD; Thomas B. Cooper, MA Background:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationHormonal contraception and PMS. Inger Sundström Poromaa Department of Women s and Children s Health Uppsala University
Hormonal contraception and PMS Inger Sundström Poromaa Department of Women s and Children s Health Uppsala University Definitions Premenstrual syndrome (PMS) ICD 10: Two symptoms, at least one psychological,
More informationStudie 083 (950E-CNS )
Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationEarly response as predictor of final remission in elderly depressed patients
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2009) Published online in Wiley InterScience (www.interscience.wiley.com).2261 Early response as predictor of final remission in
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSeasonal Affect Disorder (SAD) By, Leah Wasicka
Seasonal Affect Disorder (SAD) By, Leah Wasicka What is SAD? A pattern of major depressive episodes that occur and remit with changes in seasons Winter SAD Late Autumn through Winter Summer SAD July and
More informationSeasonal Affective Disorder
Major Depressive Disorder Seasonal Affective Disorder Current Opinion in Psychiatry, January 1994 Raymond W. Lam, M.D. Contents Summary Introduction Symptoms And Diagnosis Epidemiology Treatment of SAD
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY
Indian Journal of Psychiatry, January 29(1), pp 49-56 ANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY A total of 90 patients
More informationFDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION
FOR IMMEDIATE RELEASE FDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION First and Only Non-systemic and Non-invasive Treatment Cleared for Patients Who Have Not Benefited From Prior Antidepressant
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by New and Emerging Antidepressant Strategies in MDD Alan F. Schatzberg, MD Stanford University School of Medicine Stanford,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationWILEMAN ET AL 7 p.m. would be acceptable. They were instructed to use the light-box for 30 min a day for the 1st week, 45 min a day for the 2nd week a
BRITISH JOURNAL OF PSYCHIATRY 2001), 178, 311^316 Light therapy for seasonal affective disorder in primary care Randomised controlled trial SAMANTHA M. WILEMAN, JOHN M. EAGLES, JANE E. ANDREW, FIONAL.HOWIE,ISOBELM.CAMERON,KIRSTYMcCORMACK
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationCognitive-behavioral therapy, light therapy, and their combination in treating seasonal affective disorder
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Uniformed Services University of the Health Sciences U.S. Department of Defense 2004 Cognitive-behavioral therapy, light
More informationSeasonal Affective Disorder: A Clinical Update
Annals of Clinical Psychiatry, 19[4]:239 246, 2007 Copyright American Academy of Clinical Psychiatrists ISSN: 1040-1237 print / 1547-3325 online DOI: 10.1080/10401230701653476 Seasonal Affective Disorder:
More informationLight Therapy in Sleep Disorders 2014
Light Therapy in Sleep Disorders 2014 Andrew G Veale Light and Health Effects through the eye Effects through the skin Positive effects Mood Vitality Alertess Light on skin Vitamin D production light therapy
More informationChanges in Weight During a 1-Year Trial of Fluoxetine
Changes in Weight During a 1-Year Trial of David Michelson, M.D., Jay D. Amsterdam, M.D., Fredrick M. Quitkin, M.D., Fredrick W. Reimherr, M.D., Jerrold F. Rosenbaum, M.D., John Zajecka, M.D., Karen L.
More informationAre there differences in the responses of men and
Article Are There Differences Between Women s and Men s Antidepressant Responses? Frederic M. Quitkin, M.D. Jonathan W. Stewart, M.D. Patrick J. McGrath, M.D. Bonnie P. Taylor, M.A. Mayra S. Tisminetzky,
More informationAgomelatine Efficacy in Treating First-Episode Senile Depression
JPBS Article Agomelatine Efficacy in Treating First-Episode Senile Depression Juan Niu 1 *, Xiaoqin Chen 2, Tiantian Zhou 2, Yang Yu 3 1 Psychological Clinic of the Affiliated Hospital of Qingdao University,
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationObesity among outpatients with major depressive disorder
International Journal of Neuropsychopharmacology (2005), 8, 59 63. Copyright f 2004 CINP DOI : 10.1017/S1461145704004602 Obesity among outpatients with major depressive disorder ARTICLE George I. Papakostas,
More informationResearch Article Direct Health Care Costs of Treating Seasonal Affective Disorder: A Comparison of Light Therapy and Fluoxetine
Depression Research and Treatment Volume 2012, Article ID 628434, 5 pages doi:10.1155/2012/628434 Research Article Direct Health Care Costs of Treating Seasonal Affective Disorder: A Comparison of Light
More informationThe development of light therapy in psychiatry is closely
Reviews and Overviews The Efficacy of Light Therapy in the Treatment of Mood Disorders: A Review and Meta-Analysis of the Evidence Robert N. Golden, M.D. Bradley N. Gaynes, M.D., M.P.H. R. David Ekstrom,
More informationSubstance use and perceived symptom improvement among patients with bipolar disorder and substance dependence
Journal of Affective Disorders 79 (2004) 279 283 Brief report Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence Roger D. Weiss a,b, *, Monika
More informationUPDATE April 5, 2006 BRIEFING DOCUMENT. Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder
UPDATE April 5, 2006 BRIEFING DOCUMENT Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder 1. Introduction Selective serotonin reuptake inhibitors (SSRIs)
More informationClonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic Follow-Up Study
ISPUB.COM The Internet Journal of Mental Health Volume 2 Number 2 Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic P Dannon, I Iancu, K Lowengrub, R Amiaz,
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationBright Light Treatment: Are We Keeping Our Subjects in the Dark?
, Sleep 13(3):267-271, Raven Press, Ltd., New York 1990 Association of Professional Sleep Societies, ' Technical Note Bright Light Treatment: Are We Keeping Our Subjects in the Dark? Drew Dawson and Scott
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationExplanatory Attributions of Anxiety and Recovery in a Study of Kava
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 10, Number 3, 2004, pp. 556 559 Mary Ann Liebert, Inc. Explanatory Attributions of Anxiety and Recovery in a Study of Kava KURIAN C. ABRAHAM,
More information1. Introduction Overview Organization of Executive Summary
Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.
More informationClinical research. Treatment of seasonal affective disorders Nicole Praschak-Rieder, MD; Matthäus Willeit, MD. Pathophysiology
Treatment of seasonal affective disorders Nicole Praschak-Rieder, MD; Matthäus Willeit, MD Seasonal affective disorder (SAD) is a subform of major depressive disorder, recurrent, or bipolar disorder with
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationDepression Screening, Treatment and Follow-Up for Patients > Screening Treatment Follow-up References 4
Depression Screening, Treatment and Follow-Up for Patients > 18 Page 1. Screening 1 2. Treatment 2 3. Follow-up 3 4. References 4 Developed by: Joanette Sorkin x2500, Steve Tierney x3300, Cindy Aguiar,
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationSuicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II
Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II The Harvard community has made this article openly available. Please share how this access benefits
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationNeurobiology of Depression
Chapter 1 Neurobiology of Depression Depression can affect every aspect of life. A patient undergoing a major depressive episode who receives treatment with any antidepressant will often experience symptomatic
More informationSeasonal Affective Disorder: Diagnostic Issues
CHAPTER 1 Seasonal Affective Disorder: Diagnostic Issues Definition and diagnostic criteria Prevalence and burden Screening Clinical features Differential diagnosis Variants of SAD Further reading 1 Definition
More informationORIGINAL ARTICLE. Bright Light Treatment of Winter Depression
Bright Treatment of Winter Depression A Placebo-Controlled Trial ORIGINAL ARTICLE Charmane I. Eastman, PhD; Michael A. Young, PhD; Louis F. Fogg, PhD; Liwen Liu, PhD; Patricia M. Meaden, PhD Background:
More informationDepressive Symptoms and Family History in Seasonal and Nonseasonal Mood Disorders
Depressive Symptoms and Family History in Seasonal and Nonseasonal Mood Disorders Judith M. Allen, M.D., Raymond W. Lam, M.D., Ronald A. Remick, M.D., and Adele D. Sadovnick, Ph.D. Objective: The authors
More informationComparing Effects of Melatonin versus Trazodone on Sleep Quality in Major Depressed Patients Receiving Sertraline
2016 jpc.tums.ac.ir Comparing Effects of Melatonin versus Trazodone on Sleep Quality in Major Depressed Patients Receiving Sertraline Zahra Mirsepassi 1, Shima Saedi 2, Haleh Behpournia 3, Behrang Shadloo
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationIntroduction. Tick-Tock Goes the Clock. Page 1
Page 1 Audio-Visual Entrainment: The Application of Audio-Visual Entrainment for the Treatment of Seasonal Affective Disorder David Siever i, Edmonton, Alberta, Canada Abstract: Seasonal Affective Disorder
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationThe Role of Cognitive Factors in the Development of Seasonal Affective Disorder Episodes
The University of Maine DigitalCommons@UMaine Electronic Theses and Dissertations Fogler Library 12-2003 The Role of Cognitive Factors in the Development of Seasonal Affective Disorder Episodes Stacy Whitcomb-Smith
More informationSupplementary Online Content
Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationPartners in Care Quick Reference Cards
Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More information